v3.26.3
Segment Information
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates under a single segment based on an analysis of the Company's reporting structure, the information available to the Chief Operating Decision Maker (“CODM”), and the strategic decisions being made by management. The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical companies. Revenue is derived from clients by providing clinical cancer testing, interpretation and consultative services, molecular and NGS testing, MRD testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions.
The Company's chief executive officer serves as the CODM. The CODM uses net loss, as reported on the Consolidated Statements of Operations, to monitor budget versus actual results to evaluate profitability and allocate resources. The CODM is regularly provided with financial information, including revenue and expenses, in a format consistent with the Consolidated Statements of Operations. The CODM does not review assets at a different level or category than those disclosed in the Consolidated Balance Sheets. Substantially all of the Company's revenue and tangible long-lived assets are attributable to the U.S.
The following table summarizes segment information for the three and nine months ended September 30, 2026, and 2025 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net revenue$209,254 $187,797 $597,582 $537,162 
Less:
Amortization of intangibles7,633 7,634 22,900 24,120 
Depreciation8,555 8,802 25,912 27,309 
Stock-based compensation8,837 10,305 26,689 33,274 
Other cost of revenue(1)
104,537 99,334 304,252 280,676 
Other general and administrative(1)
51,549 52,926 149,163 156,511 
Other research and development(1)
8,932 7,465 27,325 24,426 
Other sales and marketing(1)
27,152 21,259 77,294 66,186 
Impairment charges— 7,086 — 27,127 
Loss from operations(7,941)(27,014)(35,953)(102,467)
Interest income1,196 1,563 3,683 7,547 
Interest expense(1,267)(603)(2,646)(3,154)
Other (expense) income(9)(335)(38)212 
Gain on extinguishment of debt (Note 6)— — 11,181 — 
Loss before taxes(8,021)(26,389)(23,773)(97,862)
Income tax benefit (expense)475 (740)1,359 (282)
Net loss$(7,546)$(27,129)$(22,414)$(98,144)
(1) Excludes amounts related to amortization of intangibles, depreciation, and stock-based compensation, as applicable.